高加索慢性乙型肝炎患者長期恩替卡韋或替諾福韋治療期間

StephenW

Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B
Papatheodoridis GV, Dalekos GN, Idilman R, et al.
Journal of Hepatology|August 18, 2020

Looking at patients in the multicenter European PAGE-B cohort, researchers examined if patients receiving tenofovir disoproxil fumarate (TDF) vs entecavir (ETV) differ in hepatocellular carcinoma (HCC) incidence or any other patient outcomes. They assessed 1,935 Caucasians with chronic hepatitis B (CHB), with or without compensated cirrhosis, who underwent treatment with either ETV (n = 772) or TDF (n = 1,163) monotherapy. Up to 12 years, similar rates of hepatocellular carcinoma, biochemical/virological response, HBsAg loss and mortality were seen among Caucasians with CHB treated with ETV vs TDF. However, relative to ETV treated patients, those receiving TDF more frequently had elastographic reversion of cirrhosis at year 5.

Read the full article on Journal of Hepatology.

高加索慢性乙型肝炎患者長期恩替卡韋或替諾福韋治療期間發生肝細胞癌的風險相似
Papatheodoridis GV，Dalekos GN，Idilman R等人。
肝病學雜誌| 2020年8月18日

研究人員觀察了歐洲多中心PAGE-B隊列中的患者，研究人員檢查了接受替諾福韋富馬酸替諾福韋（TDF）與恩替卡韋（ETV）的患者在肝細胞癌（HCC）發生率或任何其他患者結局方面是否存在差異。他們評估了1,935名患有或未患有代償性肝硬化的慢性乙型肝炎（CHB）的白種人，他們接受了ETV（n = 772）或TDF（n = 1,163）單藥治療。直到12年，在接受ETV和TDF治療的CHB的白種人中，肝細胞癌，生化/病毒學應答，HBsAg丟失和死亡率的發生率相似。但是，相對於接受ETV治療的患者，接受TDF的患者更經常在第5年出現彈性硬化性肝硬化逆轉。

閱讀完整的文章《肝病雜誌》。